Figure 2.
Actuarial overall survival (OS) from diagnosis for patients with and without RTK/ras-activating mutations. (A) Actuarial OS from diagnosis for all patients with and without activating mutations; (B) actuarial OS from diagnosis for patients without and with activating mutations after exclusion of FLT3/ALM patients. *P reflects log-rank comparison.